Protocol performance metrics and resource utilization of phase II investigator-initiated trials

被引：0
|
作者：
Durivage, H.
Bridges, K. D.
Sauers, J.
Wellons, M.
Baker, L.
机构：
[1] Yale Univ, Sch Med, New Haven, CT USA
[2] Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA
[3] Univ Minnesota, Masonic Can Ctr, Minneapolis, MN USA
[4] VCU Massey Canc Ctr, Richmond, VA USA
[5] Univ Texas Southwestern Simmons Canc Ctr, Dallas, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.6066
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6066
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Design and rationale for an empirical investigation of the resource use and costs of investigator-initiated randomized trials in Switzerland, the UK, and Germany
    Griessbach, Alexandra
    Speich, Benjamin
    Dutilh, Gilles
    Treweek, Shaun
    Schwenkglenks, Matthias
    Briel, Matthias
    TRIALS, 2024, 25 (01)
  • [32] An investigator-initiated phase II trial of tirabrutinib in patients with relapsed or refractory secondary CNS lymphoma
    Munakata, W.
    Goto, H.
    Fukuhara, N.
    Nagai, H.
    Arima, H.
    Kato, K.
    Kurishita, K.
    Shuda, Y.
    Isomura, R.
    Ando, Y.
    Iwaki, N.
    Sadachi, R.
    Okita, N.
    Izutsu, K.
    ANNALS OF ONCOLOGY, 2024, 35 : S1360 - S1360
  • [33] Repurposing disulfiram as treatment for metastatic colorectal cancer: An investigator-initiated clinical phase II trial
    Tarpgaard, L.
    Bartek, J.
    Pfeiffer, P.
    ANNALS OF ONCOLOGY, 2021, 32 : S174 - S175
  • [34] INFRASTRUCTURAL CAPABILITY OF INVESTIGATOR-INITIATED TRIALS INVOLVING UNAPPROVED INVESTIGATIONAL DRUGS IN JAPAN
    Shimizu, T.
    Kaneda, H.
    Tsurutani, J.
    Okamoto, K.
    Tanaka, K.
    Ohnishi, R.
    Nomura, M.
    Aida, H.
    Hashii, C.
    Nakagawa, K.
    ANNALS OF ONCOLOGY, 2013, 24
  • [35] Lessons learnt from 15 years of investigator-initiated trials on axial spondyloarthritis
    Sieper, J.
    Braun, J.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2015, 74 (02): : 125 - 131
  • [36] Efficiency of eSource Direct Data Capture in Investigator-Initiated Clinical Trials in Oncology
    Yaegashi, Hiroko
    Hayashi, Yukikazu
    Takeda, Makoto
    Chiu, Shih-Wei
    Nakayama, Haruhiko
    Ito, Hiroyuki
    Takano, Atsushi
    Tsuboi, Masahiro
    Teramoto, Koji
    Suzuki, Hiroyuki
    Kato, Tatsuya
    Yasui, Hiroshi
    Nagamura, Fumitaka
    Daigo, Yataro
    Yamaguchi, Takuhiro
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2024, 58 (06) : 1031 - 1041
  • [37] Academic investigator-initiated trials and the challenge of sponsor responsibility: the Cologne Sponsor Model
    Georgias, Christine
    Grunow, Andrea
    Olderog, Miriam
    May, Alexander
    Paulus, Ursula
    CLINICAL TRIALS, 2012, 9 (06) : 781 - 787
  • [38] Investigator-initiated Clinical Trials for Neurological Diseases in Japan: Pipeline and Support Structures
    Sakushima, Ken
    Nakamura, Harumasa
    Fujihara, Kazuo
    NEUROTHERAPEUTICS, 2024, 21 (04)
  • [39] Investigator-initiated trials of targeted oncology agents: why independent research is at risk?
    Bergmann, L.
    Berns, B.
    Dalgleish, A. G.
    von Euler, M.
    Hecht, T. T.
    Lappin, G. L.
    Reed, N.
    Palmeri, S.
    Smyth, J.
    Embacher-Aichorn, S.
    Zwierzina, H.
    ANNALS OF ONCOLOGY, 2010, 21 (08) : 1573 - 1578
  • [40] Transparency and accuracy in funding investigator-initiated clinical trials: a systematic search in clinical trials databases
    Madeira, Catarina
    Santos, Francisco
    Kubiak, Christine
    Demotes, Jacques
    Monteiro, Emilia Carreira
    BMJ OPEN, 2019, 9 (05):
12345